Everolimus 7.5 mg/1 (Everolimus TABLET) 7.5 mg/1

Everolimus 7.5 mg tablets are an oral medication used to manage various health conditions. This prescription drug is designed to support specific therapeutic needs, often related to immune response and cell growth regulation.

Strength

7.5 mg/1

Pack Size

30 TABLET in 1 BOTTLE (0054-0497-13)

Manufacturer / TM Owner

Hikma Pharmaceuticals USA Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Everolimus is primarily used to manage conditions that involve abnormal cell growth or immune system regulation. It is often prescribed for conditions where controlling cell proliferation is crucial. Patients may wonder, 'What is Everolimus used for?' This medication is typically utilized in scenarios requiring precise immune modulation or targeted therapy.

Side Effects

Common effects of Everolimus may include fatigue, mouth sores, and mild gastrointestinal discomfort. Some individuals might experience skin reactions or changes in blood cell counts. These effects can vary widely among users, and it's important to monitor any unusual symptoms.

Precautions & Warnings

Everolimus should be handled with care, following the guidance of a healthcare provider. It is essential to avoid crushing or breaking the tablets unless instructed otherwise. Patients should be aware of potential interactions with other medications and discuss any existing health conditions with their doctor.

Avoid Interactions

Everolimus may interact with certain medications, including those that affect liver enzymes like CYP3A4. It is advisable to inform your healthcare provider about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Frequently Asked Questions

Everolimus is used to manage conditions involving abnormal cell growth or immune system regulation, often in targeted therapy.

Everolimus tablets should be taken orally, typically with or without food, as directed by a healthcare provider.

Common side effects may include fatigue, mouth sores, and mild gastrointestinal discomfort.

Everolimus tablets should not be crushed or broken unless specifically instructed by a healthcare provider.

If you miss a dose, consult your healthcare provider for guidance on when to take the next dose.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.